• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

淋巴结清扫和阳性淋巴结对接受根治性肾切除术治疗的当代pT期非转移性肾细胞癌患者癌症特异性死亡率的影响。

The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT non-metastatic renal cell carcinoma treated with radical nephrectomy.

作者信息

Marchioni Michele, Bandini Marco, Pompe Raisa S, Martel Tristan, Tian Zhe, Shariat Shahrokh F, Kapoor Anil, Cindolo Luca, Briganti Alberto, Schips Luigi, Capitanio Umberto, Karakiewicz Pierre I

机构信息

Department of Urology, SS Annunziata Hospital, 'G. D'Annunzio' University of Chieti, Chieti, Italy.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.

出版信息

BJU Int. 2018 Mar;121(3):383-392. doi: 10.1111/bju.14024. Epub 2017 Oct 12.

DOI:10.1111/bju.14024
PMID:28940649
Abstract

OBJECTIVE

To assess the effect of lymph node dissection (LND), number of removed nodes (NRN), and number of positive nodes (NPN), on cancer-specific mortality (CSM) in contemporary vs historical patients with pT N M renal cell carcinoma (RCC) treated with radical nephrectomy (RN).

PATIENTS AND METHODS

Within the Surveillance, Epidemiology, and End Results database (2001-2013), we identified patients with non-metastatic pT N RCC who underwent RN with or without LND. Kaplan-Meier analyses and multivariable Cox regression models with propensity score weighting for inverse probability of treatment were used.

RESULTS

Of 25 357 patients, 24.8% underwent LND (2001-2007: 3 167 patients vs 2008-2013: 3 133 patients). The median NRN was 3 (interquartile range [IQR]: 1-7). Positive nodes were identified in 17.1%: 9.3% of pT and 21.6% of pT patients, who underwent LND. The median NPN was 2 (IQR: 1-3). In multivariable models, LND did not decrease CSM (hazard ratio [HR] 1.29; P < 0.001). LND extent, defined as NRN, did not decrease CSM (HR 0.94; P = 0.3). Finally, multivariable models testing the effect of NPN showed increased CSM in pT but not in pT patients (HR 1.29 and 1.58, P = 0.02 and P = 0.1, respectively). NRN exerted a protective effect on CSM in patients with positive nodes (HR 0.98; P = 0.007).

CONCLUSION

In contemporary and historical patients LND or its extent do not protect from CSM. However, the NPN increases the rate of CSM in pT patients. Consequently, LND and its extent appear to have little if any therapeutic value in pT N M patients, besides its prognostic impact. High-risk non-metastatic patients may represent a target population for a multi-institutional prospective trial.

摘要

目的

评估淋巴结清扫术(LND)、切除淋巴结数量(NRN)及阳性淋巴结数量(NPN)对接受根治性肾切除术(RN)治疗的当代及历史时期pT N M期肾细胞癌(RCC)患者癌症特异性死亡率(CSM)的影响。

患者与方法

在监测、流行病学与最终结果数据库(2001 - 2013年)中,我们识别出接受了有或无LND的RN治疗的非转移性pT N RCC患者。采用Kaplan - Meier分析以及带有倾向评分加权的多变量Cox回归模型来处理治疗的逆概率。

结果

在25357例患者中,24.8%接受了LND(2001 - 2007年:3167例患者,2008 - 2013年:3133例患者)。NRN的中位数为3(四分位间距[IQR]:1 - 7)。17.1%的患者发现有阳性淋巴结:接受LND的pT患者中为9.3%,pT患者中为21.6%。NPN的中位数为2(IQR:1 - 3)。在多变量模型中,LND并未降低CSM(风险比[HR] 1.29;P < 0.001)。以NRN定义的LND范围也未降低CSM(HR 0.94;P = 0.3)。最后,测试NPN影响的多变量模型显示,pT患者的CSM升高,但pT患者未升高(HR分别为1.29和1.58,P分别为0.02和0.1)。NRN对有阳性淋巴结的患者的CSM有保护作用(HR 0.98;P = 0.007)。

结论

在当代及历史时期患者中,LND或其范围并不能预防CSM。然而,NPN会增加pT患者的CSM发生率。因此,除了其预后影响外,LND及其范围在pT N M患者中似乎几乎没有治疗价值。高危非转移性患者可能是多机构前瞻性试验的目标人群。

相似文献

1
The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT non-metastatic renal cell carcinoma treated with radical nephrectomy.淋巴结清扫和阳性淋巴结对接受根治性肾切除术治疗的当代pT期非转移性肾细胞癌患者癌症特异性死亡率的影响。
BJU Int. 2018 Mar;121(3):383-392. doi: 10.1111/bju.14024. Epub 2017 Oct 12.
2
Extent of lymph node dissection improves overall survival in pT3N0 non-metastatic renal cell carcinoma patients treated with radical nephrectomy: a propensity score-based analysis.淋巴结清扫范围改善了根治性肾切除术后 pT3N0 无转移肾细胞癌患者的总生存:基于倾向评分的分析。
World J Urol. 2020 Jun;38(6):1579-1585. doi: 10.1007/s00345-019-02788-6. Epub 2019 May 7.
3
Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis.根治性肾切除术联合或不联合淋巴结清扫术治疗非转移性肾细胞癌:基于倾向评分的分析。
Eur Urol. 2017 Apr;71(4):560-567. doi: 10.1016/j.eururo.2016.09.019. Epub 2016 Sep 24.
4
Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data.淋巴结清扫术的范围并不能提高有淋巴结转移的肾细胞癌患者的生存率:与缺失数据处理相关的偏倚。
BJU Int. 2014 Jan;113(1):36-42. doi: 10.1111/j.1464-410X.2012.11693.x. Epub 2013 Mar 12.
5
Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software.使用 X-tile 软件对局限性高危肾细胞癌的淋巴结清扫进行评估。
Int Urol Nephrol. 2020 Feb;52(2):253-262. doi: 10.1007/s11255-019-02307-x. Epub 2019 Oct 14.
6
The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.根治性前列腺切除术治疗转移性前列腺癌患者淋巴结清扫的影响:生存和术后早期结局的当代分析。
Eur Urol Oncol. 2019 Sep;2(5):541-548. doi: 10.1016/j.euo.2018.10.010. Epub 2018 Nov 22.
7
The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma.淋巴结清扫范围确实会影响经病理证实的T4期肾细胞癌的癌症特异性生存率。
Urologia. 2012 Apr-Jun;79(2):109-15. doi: 10.5301/RU.2012.9255.
8
Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma.模拟针对肾细胞癌的根治性肾切除术联合或不联合淋巴结清扫术的临床试验。
Urology. 2020 Jun;140:98-106. doi: 10.1016/j.urology.2020.01.039. Epub 2020 Mar 4.
9
Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort.在无远处转移的情况下,淋巴结阳性肾细胞癌:基于人群队列的癌症特异性死亡率的预测因子。
BJU Int. 2012 Jul;110(2 Pt 2):E21-7. doi: 10.1111/j.1464-410X.2011.10701.x. Epub 2011 Nov 1.
10
Lymph Node Density as an Independent Prognostic Factor in Node-Positive Renal-Cell Carcinoma: Results From the Surveillance, Epidemiology, and End Results Program.淋巴结密度作为淋巴结阳性肾细胞癌的独立预后因素:来自监测、流行病学和最终结果计划的结果。
Clin Genitourin Cancer. 2019 Oct;17(5):e968-e980. doi: 10.1016/j.clgc.2019.05.011. Epub 2019 May 27.

引用本文的文献

1
Renal cell cancer treatment: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) surgery-focused consensus update.肾细胞癌治疗:拉丁美洲肿瘤协作组(LACOG)和拉丁美洲肾癌组(LARCG)以手术为重点的共识更新
Ther Adv Urol. 2025 Apr 14;17:17562872241312581. doi: 10.1177/17562872241312581. eCollection 2025 Jan-Dec.
2
TRENDS IN SURGICAL MANAGEMENT OF RENAL NEOPLASMS: SINGLE CENTER RESULTS IN THE LAST DECADE.过去十年中肾脏肿瘤外科治疗趋势:单中心结果。
Acta Clin Croat. 2023 Jul;62(Suppl2):53-59. doi: 10.20471/acc.2023.62.s2.8.
3
Construction of the prognostic model in non-metastatic renal cancer patients with venous tumor thrombus.
非转移性肾细胞癌伴静脉瘤栓患者预后模型的构建。
Transl Androl Urol. 2023 Nov 30;12(11):1645-1657. doi: 10.21037/tau-23-341. Epub 2023 Nov 14.
4
Editorial: History, advantages, complications, and limits of minimally invasive urologic pelvic surgery.社论:微创泌尿外科盆腔手术的历史、优势、并发症及局限性
Front Surg. 2023 Nov 21;10:1260951. doi: 10.3389/fsurg.2023.1260951. eCollection 2023.
5
The Current Role of Lymph Node Dissection in Nonmetastatic Localized Renal Cell Carcinoma.淋巴结清扫术在非转移性局限性肾细胞癌中的当前作用
J Clin Med. 2023 May 29;12(11):3732. doi: 10.3390/jcm12113732.
6
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?如何优化辅助帕博利珠单抗在肾细胞癌中的应用:哪些患者获益最大?
World J Urol. 2022 Nov;40(11):2667-2673. doi: 10.1007/s00345-022-04153-6. Epub 2022 Sep 20.
7
Potential benefit of lymph node dissection during radical nephrectomy for kidney cancer: A review and critical analysis of current literature.肾癌根治性肾切除术期间淋巴结清扫的潜在益处:当前文献综述与批判性分析
Asian J Urol. 2022 Jul;9(3):215-226. doi: 10.1016/j.ajur.2022.03.007. Epub 2022 May 27.
8
The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis.淋巴结清扫术在非转移性肾细胞癌中的作用:一项更新的系统评价和荟萃分析
Front Oncol. 2022 Jan 12;11:790381. doi: 10.3389/fonc.2021.790381. eCollection 2021.
9
Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy.局限性透明细胞肾细胞癌的预后因素及其在辅助治疗中的应用
Cancers (Basel). 2022 Jan 4;14(1):239. doi: 10.3390/cancers14010239.
10
Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art.肾细胞癌复发的生物标志物:现状。
Curr Urol Rep. 2021 Apr 22;22(6):31. doi: 10.1007/s11934-021-01050-0.